Elan accuses rebel director of insider trading

In an unusual twist to a boardroom spat at Elan, the Irish drugmaker has reported one of its own directors to the U.S. Securities and Exchange Commission for potential insider-trading allegations. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.